Paul Ardayfio

4.9k total citations · 2 hit papers
33 papers, 1.7k citations indexed

About

Paul Ardayfio is a scholar working on Physiology, Cellular and Molecular Neuroscience and Psychiatry and Mental health. According to data from OpenAlex, Paul Ardayfio has authored 33 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 10 papers in Cellular and Molecular Neuroscience and 9 papers in Psychiatry and Mental health. Recurrent topics in Paul Ardayfio's work include Alzheimer's disease research and treatments (10 papers), Dementia and Cognitive Impairment Research (6 papers) and Neurotransmitter Receptor Influence on Behavior (5 papers). Paul Ardayfio is often cited by papers focused on Alzheimer's disease research and treatments (10 papers), Dementia and Cognitive Impairment Research (6 papers) and Neurotransmitter Receptor Influence on Behavior (5 papers). Paul Ardayfio collaborates with scholars based in United States, United Kingdom and Singapore. Paul Ardayfio's co-authors include John R. Sims, Sergey Shcherbinin, Cynthia Evans, Kwang‐Soo Kim, Albert Lo, Mirosław Bryś, Stephen Salloway, Mark A. Mintun, Scott W. Andersen and JonDavid Sparks and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Neuroscience.

In The Last Decade

Paul Ardayfio

31 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Donanemab in Early Alzheimer’s Disease

2021 969 citations Mark A. Mintun, Albert Lo et al. New England Journal of Medicine profile →
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease

2025 29 citations Jennifer A. Zimmer, Paul Ardayfio et al. JAMA Neurology profile →

Peers

Countries citing papers authored by Paul Ardayfio

Since Specialization

Citations

This map shows the geographic impact of Paul Ardayfio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Ardayfio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Ardayfio more than expected).

Fields of papers citing papers by Paul Ardayfio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Ardayfio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Ardayfio. The network helps show where Paul Ardayfio may publish in the future.

Co-authorship network of co-authors of Paul Ardayfio

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Ardayfio. A scholar is included among the top collaborators of Paul Ardayfio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Ardayfio. Paul Ardayfio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension 2025 ·The Journal of Prevention of Alzheimer s Disease ·Jennifer A. Zimmer, John R. Sims, Cynthia Evans, Emel Serap Monkul Nery, Hong Wang, Alette M. Wessels, Giulia Tronchin, Shoichiro Sato, Lars Lau Rakêt, Scott W. Andersen, Christophe Sapin, (unknown), Ivelina Gueorguieva, Paul Ardayfio, Rashna Khanna, Dawn A. Brooks, Brandy R. Matthews, Mark A. Mintun	0
2	The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6 2025 ·The Journal of Prevention of Alzheimer s Disease ·Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Sergey Shcherbinin, Wen Xu, Scott W. Andersen, Paula M. Hauck, Dawn A. Brooks, (unknown), Stephen Salloway, Mark A. Mintun, John R. Sims	2
3	Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease breakdown → 2025 ·JAMA Neurology ·Jennifer A. Zimmer, Paul Ardayfio, Hong Wang, Rashna Khanna, Cynthia Evans, Ming Lu, JonDavid Sparks, Scott W. Andersen, (unknown), Emel Serap Monkul Nery, (unknown), Staci E. Engle, Alessandro Biffi, Diana Otero Svaldi, Stephen Salloway, Steven M. Greenberg, Reisa A. Sperling, Mark A. Mintun, Dawn A. Brooks, John R. Sims	29
4	1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial 2024 ·Age and Ageing ·Mark A. Mintun, Craig Ritchie, Paul R. Solomon, John R. Sims, Stephen Salloway, Oskar Hansson, Liana G. Apostolova, (unknown), C D Evans, Ming‐Chi Lu, Paul Ardayfio, Janet D. Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, (unknown), Ellen B. Dennehy, Doug A. Brooks, Daniel Skovronsky, (unknown), (unknown)	2
5	Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial 2023 ·Alzheimer s & Dementia ·Mark A. Mintun, Craig Ritchie, Paul R. Solomon, John R. Sims, Stephen Salloway, Oskar Hansson, Liana G. Apostolova, Jennifer A. Zimmer, Cynthia Evans, Ming Lu, Paul Ardayfio, JonDavid Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Emily C. Collins, Ellen B. Dennehy, Dawn A. Brooks, Daniel Skovronsky	6
6	Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease 2023 ·Clinical Pharmacology & Therapeutics ·Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Kay Hoong Chow, C. Steven Ernest, Sergey Shcherbinin, Paul Ardayfio, Garrett R. Mullins, John R. Sims	46
7	Donanemab in Early Alzheimer’s Disease breakdown → 2021 ·New England Journal of Medicine ·Mark A. Mintun, Albert Lo, Cynthia Evans, Alette M. Wessels, Paul Ardayfio, Scott W. Andersen, Sergey Shcherbinin, JonDavid Sparks, John R. Sims, Mirosław Bryś, Liana G. Apostolova, Stephen Salloway, Daniel Skovronsky	969
8	Results of the Presence Study Evaluating Mevidalen for the Treatment of Lewy Body Dementia (LBD) (2028) 2021 ·Neurology ·Kevin Biglan, Leanne Munsie, Kjell Svensson, Paul Ardayfio, (unknown), John R. Sims, Mark A. Mintun	1
9	Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging 2021 ·The Journal of Prevention of Alzheimer s Disease ·Stephen L. Lowe, Cynthia Evans, Sergey Shcherbinin, (unknown), Brian A. Willis, Ivelina Gueorguieva, Albert Lo, Adam Fleisher, Jeffrey L. Dage, Paul Ardayfio, (unknown), (unknown), (unknown), Lynette J. Chua, Garrett R. Mullins, John R. Sims	74
10	Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis 2019 ·Drug Safety ·(unknown), Arie Regev, Paul Ardayfio, Naga Chalasani	19
11	Considerations on nonclinical approaches to modeling risk factors of suicidal ideation and behavior 2017 ·Regulatory Toxicology and Pharmacology ·(unknown), (unknown), (unknown), Mary Jeanne Kallman, (unknown), (unknown), Alessandra Giarola, Paul Ardayfio, John A. Moyer, (unknown), Thomas J. Hudzik	4
12	Consequences of constitutive deletion of melanin-concentrating hormone-1 receptors for feeding and foraging behaviors of mice 2016 ·Behavioural Brain Research ·William J.A. Eiler, Yanyun Chen, Lawrence J. Slieker, Paul Ardayfio, Michael A. Statnick, Jeffrey M. Witkin	4
13	Pitx3-deficient aphakia mice display unique behavioral responses to psychostimulant and antipsychotic drugs 2009 ·Neuroscience ·Paul Ardayfio, Amanda Leung, (unknown), Dong‐Youn Hwang, Taylor Moran‐Gates, Yong Kee Choi, William A. Carlezon, Frank I. Tarazi, (unknown)	13
14	Preclinical Evaluation of Melanin-Concentrating Hormone Receptor 1 Antagonism for the Treatment of Obesity and Depression 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Donald R. Gehlert, Kurt Rasmussen, Janice Shaw, Xia Li, Paul Ardayfio, (unknown), Tamer Coşkun, Hong Y. Zhang, Yanyun Chen, Jeffrey M. Witkin	62
15	Impaired learning and memory in Pitx3 deficient aphakia mice: A genetic model for striatum-dependent cognitive symptoms in Parkinson's disease 2008 ·Neurobiology of Disease ·Paul Ardayfio, Jisook Moon, (unknown), (unknown), Kwang‐Soo Kim	39
16	The 5-Hydroxytryptamine2A Receptor Antagonist R-(+)-α-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) Attenuates Impulsivity after Both Drug-Induced Disruption (Dizocilpine) and Enhancement (Antidepressant Drugs) of Differential-Reinforcement-of-Low-Rate 72-s Behavior in the Rat 2008 ·Journal of Pharmacology and Experimental Therapeutics ·Paul Ardayfio, Mark J. Benvenga, (unknown), Patrick L. Love, John T. Catlow, Steven P. Swanson, Gerard J. Marek	20
17	Anxiogenic-like effect of chronic corticosterone in the light-dark emergence task in mice. 2006 ·Behavioral Neuroscience ·Paul Ardayfio, Kwang‐Soo Kim	97
18	Acoustic startle, conditioned startle potentiation and the effects of 8-OH-DPAT and buspirone in rats selectively bred for differences in 8-OH-DPAT-induced hypothermia 2001 ·Behavioural Pharmacology ·David A. McQueen, David H. Overstreet, Paul Ardayfio, Randall L. Commissaris	11
19	A nonextinction procedure for long-term studies of classically conditioned enhancement of acoustic startle in the rat 2001 ·Physiology & Behavior ·(unknown), (unknown), Paul Ardayfio, Caroline Beard, Randall L. Commissaris	11
20	An E-box Motif Residing in the Exon/Intron 1 Junction Regulates Both Transcriptional Activation and Splicing of the Human Norepinephrine Transporter Gene 2001 ·Journal of Biological Chemistry ·Chun‐Hyung Kim, Paul Ardayfio, Kwang‐Soo Kim	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact